# Vepugratinib

Source: https://onco.cc/drugs/vepugratinib/  
OnCo record `vepugratinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vepugratinib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.

## Summary

Vepugratinib is a small-molecule drug developed by Eli Lilly and. The sponsor describes its target as FGFR3, which OnCo does not yet have a target page for. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07218380 (A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract), in bladder & urothelial cancer. The largest, NCT07218380, plans to enrol 450 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Vepugratinib: https://clinicaltrials.gov/search?intr=Vepugratinib

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- trials: [A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract](https://onco.cc/trials/nct07218380/)

---
JSON: https://onco.cc/api/v1/entities/vepugratinib.json